MESA LABORATORIES INC (MLAB) Stock Fundamental Analysis
USA - NASDAQ:MLAB - US59064R1095 - Common Stock
74.2 USD
+0.46 (+0.62%)
74.2 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to MLAB. MLAB was compared to 58 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of MLAB while its profitability can be described as average. MLAB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year MLAB was profitable.
In the past year MLAB had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
In the past 5 years MLAB always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -0.14%, MLAB is in the better half of the industry, outperforming 65.52% of the companies in the same industry.
MLAB's Return On Equity of -0.36% is fine compared to the rest of the industry. MLAB outperforms 67.24% of its industry peers.
MLAB has a better Return On Invested Capital (3.81%) than 65.52% of its industry peers.
MLAB had an Average Return On Invested Capital over the past 3 years of 1.90%. This is significantly below the industry average of 13.50%.
The last Return On Invested Capital (3.81%) for MLAB is above the 3 year average (1.90%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.36% | ||
| ROIC | 3.81% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
1.3 Margins
With a decent Operating Margin value of 5.70%, MLAB is doing good in the industry, outperforming 62.07% of the companies in the same industry.
MLAB's Operating Margin has been stable in the last couple of years.
MLAB has a better Gross Margin (62.12%) than 82.76% of its industry peers.
In the last couple of years the Gross Margin of MLAB has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.7% | ||
| PM (TTM) | N/A | ||
| GM | 62.12% |
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MLAB is destroying value.
The number of shares outstanding for MLAB has been increased compared to 1 year ago.
Compared to 5 years ago, MLAB has more shares outstanding
The debt/assets ratio for MLAB has been reduced compared to a year ago.
2.2 Solvency
MLAB has an Altman-Z score of 0.86. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MLAB (0.86) is worse than 62.07% of its industry peers.
MLAB has a debt to FCF ratio of 5.38. This is a neutral value as MLAB would need 5.38 years to pay back of all of its debts.
MLAB has a better Debt to FCF ratio (5.38) than 67.24% of its industry peers.
MLAB has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
MLAB has a worse Debt to Equity ratio (0.46) than 60.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 5.38 | ||
| Altman-Z | 0.86 |
ROIC/WACC0.38
WACC10.17%
2.3 Liquidity
A Current Ratio of 0.66 indicates that MLAB may have some problems paying its short term obligations.
MLAB has a worse Current ratio (0.66) than 94.83% of its industry peers.
A Quick Ratio of 0.47 indicates that MLAB may have some problems paying its short term obligations.
MLAB's Quick ratio of 0.47 is on the low side compared to the rest of the industry. MLAB is outperformed by 94.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.47 |
3. Growth
3.1 Past
MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -98.30%.
Measured over the past years, MLAB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -39.16% on average per year.
MLAB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.33%.
The Revenue has been growing by 15.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-98.3%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%1.19%
Revenue 1Y (TTM)8.33%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%2.36%
3.2 Future
MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 231.94% yearly.
The Revenue is expected to grow by 4.58% on average over the next years.
EPS Next Y2471.86%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.58%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MLAB is valuated quite expensively with a Price/Earnings ratio of 927.50.
MLAB's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.13, MLAB is valued quite expensively.
Based on the Price/Forward Earnings ratio of 48.02, the valuation of MLAB can be described as expensive.
MLAB's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.35, MLAB is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 927.5 | ||
| Fwd PE | 48.02 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MLAB indicates a rather cheap valuation: MLAB is cheaper than 89.66% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MLAB indicates a rather cheap valuation: MLAB is cheaper than 98.28% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.13 | ||
| EV/EBITDA | 14.62 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MLAB has a very decent profitability rating, which may justify a higher PE ratio.
MLAB's earnings are expected to grow with 231.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y369.85%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
With a yearly dividend of 0.84%, MLAB is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.49, MLAB pays a better dividend. On top of this MLAB pays more dividend than 100.00% of the companies listed in the same industry.
With a Dividend Yield of 0.84, MLAB pays less dividend than the S&P500 average, which is at 2.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.84% |
5.2 History
The dividend of MLAB decreases each year by -0.50%.
MLAB has paid a dividend for at least 10 years, which is a reliable track record.
MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
MLAB has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-560.97%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
74.2
+0.46 (+0.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners96.24%
Inst Owner Change-7.73%
Ins Owners5.28%
Ins Owner Change6.18%
Market Cap408.10M
Revenue(TTM)242.35M
Net Income(TTM)-620000
Analysts80
Price Target90.27 (21.66%)
Short Float %6.6%
Short Ratio2.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.84% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-560.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-63.49%
Min EPS beat(2)-217.83%
Max EPS beat(2)90.84%
EPS beat(4)1
Avg EPS beat(4)-71.19%
Min EPS beat(4)-217.83%
Max EPS beat(4)90.84%
EPS beat(8)4
Avg EPS beat(8)363.88%
EPS beat(12)5
Avg EPS beat(12)215.08%
EPS beat(16)7
Avg EPS beat(16)149.42%
Revenue beat(2)0
Avg Revenue beat(2)-2.31%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-0.98%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.52%
Revenue beat(12)4
Avg Revenue beat(12)-1.1%
Revenue beat(16)6
Avg Revenue beat(16)0.34%
PT rev (1m)0%
PT rev (3m)-26.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-40%
EPS NY rev (1m)0%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 927.5 | ||
| Fwd PE | 48.02 | ||
| P/S | 1.68 | ||
| P/FCF | 12.13 | ||
| P/OCF | 10.66 | ||
| P/B | 2.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.62 |
EPS(TTM)0.08
EY0.11%
EPS(NY)1.55
Fwd EY2.08%
FCF(TTM)6.12
FCFY8.25%
OCF(TTM)6.96
OCFY9.38%
SpS44.06
BVpS31.36
TBVpS-20.54
PEG (NY)0.38
PEG (5Y)N/A
Graham Number7.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.36% | ||
| ROCE | 4.83% | ||
| ROIC | 3.81% | ||
| ROICexc | 4.12% | ||
| ROICexgc | N/A | ||
| OM | 5.7% | ||
| PM (TTM) | N/A | ||
| GM | 62.12% | ||
| FCFM | 13.89% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
ROICexc(3y)2.1%
ROICexc(5y)2.03%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.4%
ROCE(5y)2.02%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y106.13%
ROICexc growth 5Y21.15%
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 5.38 | ||
| Debt/EBITDA | 2.05 | ||
| Cap/Depr | 18.45% | ||
| Cap/Sales | 1.91% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.53% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.47 | ||
| Altman-Z | 0.86 |
F-Score5
WACC10.17%
ROIC/WACC0.38
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-98.3%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%1.19%
EPS Next Y2471.86%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)8.33%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%2.36%
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.58%
Revenue Next 5YN/A
EBIT growth 1Y58.81%
EBIT growth 3Y51.48%
EBIT growth 5Y15.93%
EBIT Next Year171.2%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y-6.91%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-6.04%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to MLAB.
Can you provide the valuation status for MESA LABORATORIES INC?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
How profitable is MESA LABORATORIES INC (MLAB) stock?
MESA LABORATORIES INC (MLAB) has a profitability rating of 6 / 10.
What is the valuation of MESA LABORATORIES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MESA LABORATORIES INC (MLAB) is 927.5 and the Price/Book (PB) ratio is 2.37.
How sustainable is the dividend of MESA LABORATORIES INC (MLAB) stock?
The dividend rating of MESA LABORATORIES INC (MLAB) is 4 / 10 and the dividend payout ratio is -560.97%.